Scholarlink

<p>Upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, has gained FDA approval for conditions such as rheumatoid arthritis and atopic dermatitis. Emerging studies suggest its potential for off-label use in various dermatological disorders. This review systematically explores the off-label dermatological applications of upadacitinib. We conducted a comprehensive literature search across MEDLINE, EMBASE, SCOPUS, and ClinicalTrials.gov. Studies on alopecia areata, hidradenitis suppurativa, vitiligo, and other conditions were included. The review identified two randomized controlled trials (RCTs) evaluating upadacitinib’s efficacy in hidradenitis suppurativa and vitiligo. Both trials demonstrated promising improvements in clinical outcomes, though some results were not statistically significant. Additionally, case reports and series highlight its efficacy in alopecia areata and lichen planus. These findings suggest upadacitinib as a viable option for refractory dermatological conditions. However, the limited sample sizes and short follow-up periods underscore the need for further large-scale, long-term studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Off-label use of JAK1 inhibitor upadacitinib in dermatology

  • 期刊论文

  • 发表日期：

    2025年2月7日

查看全文
  • Tian-Yi Zhang,
  • Yue-Ping Zeng

摘要

Upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, has gained FDA approval for conditions such as rheumatoid arthritis and atopic dermatitis. Emerging studies suggest its potential for off-label use in various dermatological disorders. This review systematically explores the off-label dermatological applications of upadacitinib. We conducted a comprehensive literature search across MEDLINE, EMBASE, SCOPUS, and ClinicalTrials.gov. Studies on alopecia areata, hidradenitis suppurativa, vitiligo, and other conditions were included. The review identified two randomized controlled trials (RCTs) evaluating upadacitinib’s efficacy in hidradenitis suppurativa and vitiligo. Both trials demonstrated promising improvements in clinical outcomes, though some results were not statistically significant. Additionally, case reports and series highlight its efficacy in alopecia areata and lichen planus. These findings suggest upadacitinib as a viable option for refractory dermatological conditions. However, the limited sample sizes and short follow-up periods underscore the need for further large-scale, long-term studies.